The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a…

This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics…

This CEC Oncology ONS Chapters Series is targeted to oncology nurses and advanced nurse practitioners serving as part of an interprofessional healthcare team providing care for pediatric and adult patients with acute lymphoblastic leukemia (ALL) and…